The earnings call presented a mixed picture with several strategic advancements and organic growth offset by regional performance issues and currency headwinds. The company's strategic initiatives and innovation efforts show potential for future growth, but current challenges in certain markets and financial metrics present areas of concern.

Company Guidance

In the CellaVision Q3 2025 report, CEO Simon Østergaard discussed a softer quarter with mixed regional performance, influenced by currency effects. Net sales decreased by 1.7% to SEK 176 million, though organic sales grew by 2.6% compared to the previous year, despite a 4.3% FX headwind. EBITDA increased slightly to SEK 50 million, equating to a 28% margin. The company emphasized its strategic progress, including the completion of a clinical trial and submission for CE Marking of its bone marrow application, expected early 2026. They also highlighted an upgraded software for their platforms, set to roll out in the current quarter. Gross margin improved to 69%, aided by price increases and product mix adjustments. Operating expenses totaled SEK 82 million, with significant R&D investments accounting for 24% of sales, although capitalization was lower at SEK 14 million. The operating cash flow was SEK 29.6 million, with a total cash flow of SEK 4 million after investments and finance activities. Regionally, the Americas saw SEK 68 million in sales with a 4% organic growth, while EMEA recorded SEK 96 million with 1% growth. APAC reported SEK 13 million, reflecting a 10% growth but on a low base. The company is optimistic about its strategic directions, particularly with its bone marrow application and software upgrades expected to enhance future growth.

Organic Sales Growth

Despite a net sales decrease of 1.7%, CellaVision achieved an organic sales increase of 2.6% compared to the previous year.

EBITDA Improvement

EBITDA improved from SEK 49 million to SEK 50 million, resulting in an EBITDA margin of 28%.

Progress in Strategic Projects

Completion of clinical trials and submission for CE Marking for the bone marrow application, expected by early 2026.

Reagents Segment Growth

The reagents segment saw a growth of 14%, indicating a positive trajectory in this business area.

Software and Innovation

The software upgrade was finalized and installed at customer sites, with an enhanced user experience and functionality.

CellaVision AB (SE:CEVI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SE:CEVI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 05, 2026	2025 (Q4)	1.37 / -	1.7	―	―	―
Nov 06, 2025	2025 (Q3)	1.06 / 1.30	1.3	0.38% (<+0.01)	―
Jul 18, 2025	2025 (Q2)	1.65 / 1.60	1.6	0.00% (0.00)
Apr 29, 2025	2025 (Q1)	1.38 / 1.70	1.3	30.77% (+0.40)
Feb 06, 2025	2024 (Q4)	1.89 / 1.70	2.1	-19.05% (-0.40)
Oct 24, 2024	2024 (Q3)	1.70 / 1.30	1.1	18.18% (+0.20)	―
Jul 19, 2024	2024 (Q2)	1.71 / 1.60	1.5	6.67% (+0.10)	―
Apr 25, 2024	2024 (Q1)	1.51 / 1.30	0.8	62.50% (+0.50)	―
Feb 07, 2024	2023 (Q4)	1.35 / 2.10	1.375	52.73% (+0.73)	―
Oct 25, 2023	2023 (Q3)	1.34 / 1.10	0.4	175.00% (+0.70)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SE:CEVI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	kr176.00	kr160.00	-9.09%
Jul 18, 2025	kr180.60	kr183.20	+1.44%
Apr 29, 2025	kr158.98	kr195.12	+22.73%
Feb 06, 2025	kr219.70	kr202.42	-7.87%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does CellaVision AB (SE:CEVI) report earnings?

CellaVision AB (SE:CEVI) is schdueled to report earning on Feb 05, 2026, Before Open (Confirmed).

What is CellaVision AB (SE:CEVI) earnings time?

CellaVision AB (SE:CEVI) earnings time is at Feb 05, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of CellaVision AB stock?

The P/E ratio of CellaVision AB is N/A.

What is SE:CEVI EPS forecast?

SE:CEVI EPS forecast for the fiscal quarter 2025 (Q4) is 1.37.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing